Abaucin

RS102895 is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1.

Product Specifications

CAS Number

[300815-41-2]

Product Name Alternative

RS102895; MLJS-21001

UNSPSC

12352005

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Neurological Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/RS102895.html

Purity

99.97

Solubility

DMSO : 175 mg/mL (ultrasonic) |Ethanol : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC2=CC=CC=C2C3(CCN(CCC4=CC=C(C(F)(F)F)C=C4)CC3)O1

Molecular Formula

C21H21F3N2O2

Molecular Weight

390.40

References & Citations

[1]Mirzadegan T, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem. 2000 Aug 18;275 (33) :25562-71.|[2]Park J, et al. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am J Physiol Renal Physiol. 2008 Sep;295 (3) :F749-57.|[3]Ren F, et al. Analgesic Effect of Intrathecal Administration of Chemokine Receptor CCR2 Antagonist is Related to Change in Spinal NR2B, nNOS, and SIGIRR Expression in Rat with Bone Cancer Pain. Cell Biochem Biophys. 2015 Jun;72 (2) :611-6.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

CCR1; CCR2

Citation 01

Adv Sci (Weinh) . 2025 Jul 17:e07167.|Eur J Pharmacol. 2021 Aug 5:904:174165.|Exp Cell Res. 2020 Nov 1;396 (1) :112289.|Hum Reprod. 2019 Apr 1;34 (4) :646-658.|J Eur Acad Dermatol Venereol. 2020 Apr;34 (4) :862-872.|J Interferon Cytokine Res. 2019 Apr;39 (4) :224-232. |J Interferon Cytokine Res. 2020 May;40 (5) :245-253.|Life Sci. 2020 Nov 15;261:118360.|Sci Rep. 2025 May 15;15 (1) :16869.|Stem Cell Res Ther. 2021 Jul 2;12 (1) :378.|Stem Cell Res Ther. 2025 Mar 1;16 (1) :108.|Brain Sci. 2025 Feb 27;15 (3) :255.|Cell Death Dis. 2022 Feb 17;13 (2) :158.|Int Immunopharmacol. 2023 Feb:115:109731.|J Adv Res. 2020 Jul 22;28:231-243.|J Adv Res. 2024 Apr 14:S2090-1232 (24) 00155-3.|J Neuroinflammation. 2023 Nov 17;20 (1) :270.|Liver Int. 2022 Dec;42 (12) :2696-2712.|Mol Med Rep. 2017 Sep;16 (3) :3387-3394. |Nat Immunol. 2024 Oct;25 (10) :1959-1975.|Sci Adv. 2023 Aug 2;9 (31) :eadg6856.|Theranostics. 2020 Apr 27;10 (13) :5687-5703